Nuvalent Inc (NUVL)
86.88
-3.30
(-3.66%)
USD |
NASDAQ |
Nov 15, 16:00
86.84
-0.04
(-0.05%)
After-Hours: 20:00
Nuvalent Cash from Operations (Quarterly): -45.82M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -45.82M |
| June 30, 2024 | -41.16M |
| March 31, 2024 | -36.09M |
| December 31, 2023 | -30.21M |
| September 30, 2023 | -22.98M |
| June 30, 2023 | -22.14M |
| March 31, 2023 | -24.41M |
| December 31, 2022 | -17.78M |
| September 30, 2022 | -18.18M |
| June 30, 2022 | -15.48M |
| Date | Value |
|---|---|
| March 31, 2022 | -13.54M |
| December 31, 2021 | -12.96M |
| September 30, 2021 | -11.40M |
| June 30, 2021 | -9.712M |
| March 31, 2021 | -5.933M |
| December 31, 2020 | -4.937M |
| September 30, 2020 | -4.071M |
| June 30, 2020 | -2.946M |
| March 31, 2020 | -2.995M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-45.82M
Minimum
Sep 2024
-2.946M
Maximum
Jun 2020
-18.04M
Average
-15.48M
Median
Jun 2022
Cash from Operations (Quarterly) Benchmarks
| Viking Therapeutics Inc | -21.96M |
| Bristol-Myers Squibb Co | 5.591B |
| Replimune Group Inc | -38.64M |
| Moderna Inc | -1.566B |
| NovaBay Pharmaceuticals Inc | -2.061M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -212.91M |
| Cash from Financing (Quarterly) | 550.27M |
| Free Cash Flow | -153.27M |
| Free Cash Flow Per Share (Quarterly) | -0.6976 |
| Free Cash Flow Yield | -2.75% |